PFB and AKN

Status: draft compiled 2026-04-20.

Pseudofolliculitis barbae (PFB) and acne keloidalis nuchae (AKN) are the two conditions for which laser hair removal is most clearly a medically indicated intervention rather than a cosmetic one. Insurance coverage for PFB-indicated laser often differs from cosmetic coverage, the clinical benefit is substantial and durable, and the population affected is predominantly Black men whose short-term methods (razor shaving) have exhausted their options. This chapter covers PFB and AKN in the specifically-laser context; the behavioural and short-term aspects are in ../../shortterm-deep/surface/shaving-pfb.md.

PFB — mechanism and population

PFB is covered mechanistically in the short-term chapter. The summary: curly or coiled hair shafts, close shaving (particularly with multi-blade razors that cut below the skin surface via hysteresis), and either extrafollicular or transfollicular regrowth penetration produces the foreign-body inflammatory papules that characterise the disease. Prevalence is 45-85% in Black men; smaller but real fractions in other tightly-curled-hair populations. Sources: Ogunbiyi A 2019, Clin Cosmet Investig Dermatol; Cowley 2023, PMID 36840647; JAAD Reviews 2024 PFB grooming. Confidence: C1.

The mechanism-targeted treatment is to eliminate or dramatically reduce the hair shafts in the affected field, so there are no shafts to re-enter the skin. Laser hair removal is the intervention that accomplishes this; behavioural modifications (single-blade razor, growing the beard, chemical depilatory) are partial solutions that work for less-severe disease but usually fall short of definitive control in moderate-to-severe PFB.

Long-pulsed Nd:YAG 1064 as first-line

The most robust evidence base for PFB laser treatment is with long-pulsed Nd:YAG 1064 nm on Fitzpatrick IV-VI skin. Key trials:

• Ross EV et al 2002, JAAD 47:263-270, PMID 12140465 — 2-session Nd:YAG significantly reduced papule counts in Fitz IV-VI beards compared with untreated control.
• Smith EP et al 2009, J Drugs Dermatol — n=26 Fitz IV-VI, post-treatment papule count 11.6 vs 30.1 untreated.
• [Battle EF et al 2021] in US service members (~74% Black): 88% satisfied; 70% achieving ≥75% lesion reduction; 96% able to resume shaving.
• [Emer JJ 2011 J Drugs Dermatol] — evidenced-based use of 800 nm diode laser for PFB in skin of colour.

Standard protocol: long-pulsed Nd:YAG 1064 nm, pulse width 20-40 ms, spot size 10-12 mm, fluence 30-50 J/cm² starting, 4-6 sessions at 6-8 week intervals. DCD cryogen or sapphire cooling. Expected outcome: substantial papule reduction, possible resumption of daily shaving without PFB flare, and durable benefit that often persists for years with periodic touch-ups. PFB recurrence is common over years (84% over time in Battle 2021 follow-up), so maintenance sessions every 12-24 months are reasonable. Confidence: C2.

Eflornithine + Nd:YAG as adjunct combination

Aboelsaad H / Shokeir 2021 J Cosmet Dermatol, PMID 33629488 compared eflornithine 13.9% cream (Vaniqa) + long-pulsed Nd:YAG against Nd:YAG alone for PFB and reported superior outcomes in the combination arm. The mechanism is that eflornithine slows follicular proliferation (see ../../shortterm-deep/hormonal-prereqs.md §Eflornithine) so that the per-session laser effect is compounded by continuous growth suppression between sessions. Cost is the main limitation — eflornithine cream runs $50-150/month and is usually not insurance-covered — but for refractory or severe PFB, the combination is evidence-supported and clinically meaningful. Confidence: C2.

Diode 810 as alternative

Diode 810 nm at appropriately adjusted parameters is a reasonable alternative to Nd:YAG for Fitz IV patients. Evidence: [Emer 2011] and later series. For Fitz V-VI, Nd:YAG remains the first choice. Alexandrite is contraindicated for Fitz IV-VI and should not be used for PFB in these populations. Confidence: C2.

AKN

Acne keloidalis nuchae is the PFB-equivalent condition on the occipital scalp and nape. It shares the curly-hair / close-cut mechanism but is complicated by a keloid-forming tendency so that lesions can progress to firm keloidal papules and plaques rather than just inflammatory papules. The same laser protocols apply (Nd:YAG 1064 first-line); topical and intralesional steroid are added to modulate the keloid component.

Key trials: Esmat et al 2012, PMID 23588150; [Umar 2013]; 2018 prospective controlled trial PMID 29587518. Protocol: long-pulsed Nd:YAG 1064 nm, 15-25 ms pulse, 10-12 mm spot, 30-50 J/cm²; 4-6 sessions; adjunctive topical or intralesional steroid to existing papular lesions. Effective for papular-stage disease; established large plaques may require surgical excision. Confidence: C3.

Military grooming context (US)

US Army Directive 2025-13 (effective 7 July 2025) ended permanent shaving profiles and moved affected soldiers to 12-months-in-24 temporary medical profiles with command-approved exceptions. TB MED 287 (July 2025) is the accompanying technical bulletin detailing permitted interventions (electric razor, adjustable-guard trimmer, single-blade safety razor, chemical depilatory, laser). This has sharply increased the volume of service members seeking definitive laser treatment for PFB because the alternative — continued temporary medical profiles — carries administrative risk. Military health system laser hair removal for PFB is covered under the new policy but requires specific documentation. Sources: Army.mil facial hair policy announcement; Army TB MED 287 July 2025 PDF; Air & Space Forces Magazine coverage. Confidence: C1.

Insurance coverage

Civilian insurance coverage for PFB-indicated laser hair removal is more favourable than for cosmetic hair removal but still variable. Medicare, Medicaid (state-dependent), and many commercial plans will cover laser for documented PFB with appropriate diagnosis codes (ICD-10 L73.1) and prior documentation of failed conservative therapy (behavioural modifications, topical pharmacology). The key clinical documentation: photograph of active papules; papule count; prior-treatment trials (razor type, depilatory trials, topical pharmacology); functional impairment (inability to perform occupational shaving requirements); PIH or scarring from untreated disease. A clinician writing "Laser hair removal for PFB" without this supporting documentation often gets denied; the same request with 2-3 paragraphs of clinical supporting context and photographs is usually approved. Confidence: C3.

Combination regimen

An evidence-consistent PFB treatment regimen combining the available modalities looks something like:

1. Grooming modification: single-blade safety razor or electric foil or growing the beard 1/4 inch during active flares.
2. Topical daily: glycolic acid 8-15% lotion, benzoyl peroxide 2.5-5%, topical retinoid.
3. Laser course: long-pulsed Nd:YAG 1064 nm, 4-6 sessions at 6-8 week intervals, 30-50 J/cm² starting.
4. Eflornithine 13.9% cream during the laser course if refractory or severe.
5. Maintenance: periodic Nd:YAG touch-ups every 12-24 months as needed.
6. PIH management: photoprotection, hydroquinone, azelaic acid, topical or oral tranexamic acid for persistent pigmentation.

This stacked regimen is the practical standard in modern dermatology for moderate-to-severe PFB and produces durable control in most patients. Confidence: C3.